Iceland· IS-EU/1/05/319/005-007+018-020
Xolair
A omalizumab product containing omalizumabum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 16 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Omalizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX05 (omalizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Omalizumab · ATC R03DX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of omalizumab costs, country by country.
Normalised to the WHO defined daily dose (16 mg), the median price runs from $0.26 in Czechia to $48.02 in Switzerland — a ×186 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Omalizumab · price per daily dose (16 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.02
- CZ Czechia$0.26
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Omalizumabum INN
- Manufacturer
- Novartis Europharm Limited*
- Country
- Iceland (IS)
- ATC code
- R03DX05
- ATC class
- Omalizumab
- Defined daily dose
- 16 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for omalizumab.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Omalizumab · interactions on record
8 records
- 1 moderate
- 7 minor
Most severe, free to view
- Omacetaxine mepesuccinateL01XX40moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Omalizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOMLYCLOCelltrion Healthcare Hungary Kft., Budapest
- SwedenOmlyclo 75 mg Injektionsvätska, lösning i förfylld injektionspennaCelltrion Healthcare Hungary Kft
- PolandOmlycloCelltrion Healthcare Hungary Kft.
- BelgiumOmlyclo 75 mgCelltrion Healthcare Hungary
- SpainOMLYCLO 75 MG SOLUCION INYECTABLE EN JERINGA PRECARGADACelltrion Healthcare Hungary Kft.
- NorwayOmlycloCelltrion Healthcare Hungary Kft.
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
- SwitzerlandOmlyclo 150 mg/1 ml, solution injectable en seringue préremplieIQONE HEALTHCARE SWITZERLAND SA
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Omlyclo, Xolair
- Norway · Omlyclo, Xolair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd908c34-73ce-4905-b234-4d9a2771a43c GET /v1/drugs/cd908c34-73ce-4905-b234-4d9a2771a43c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "R03DX05",
"marketed": false,
"strength": "75 mg",
"ma_number": "EU/1/05/319/005-007+018-020",
"substance": "Omalizumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í ofnæmis- og lungnasjúkdómum, sérfræðinga í húðsjúkdómum og sérfræðinga í háls-, nef og eyrnalækningum",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "39993"
}See everything about omalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.